

DAFTAR PUSTAKA

1. Jiao A, Zhao Y, Chu L, Yang Y, Jin Z. A review on animal and plant proteins in regulating diabetic kidney disease: mechanism of action and future perspectives. *J Funct Foods*. 2024;119:106353.
2. Hussain S, Chand Jamali M, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: an overview of prevalence, risk factors, and biomarkers. *Clin Epidemiol Glob Health*. 2021;9:2–6.
3. Setiati S, Alwi I, Sudoyo AW, K. MS, Setiyohadi B, Syam AF, editors. *Buku ajar ilmu penyakit dalam*. 6th ed. Jakarta Pusat: Pusat Penerbitan Ilmu Penyakit Dalam; 2014.
4. Morales J, Dagogo-Jack S, Fonseca V, Neumiller JJ, Rosas SE. Perspectives on chronic kidney disease with type 2 diabetes and risk management: practical viewpoints and a paradigm shift using a pillar approach. *Clin Diabetes*. 2023;41(4):553–66.
5. Decroli E. *Diabetes melitus tipe 2*. Kam A, Efendi YP, Decroli GP, Rahmadi A, editors. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas; 2019.
6. Cheng HT, Xu X, Lim PS, Hung KY. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015. *Diabetes Care*. 2021;44(1):89–97.
7. Deng Y, Li N, Wu Y, Wang M, Yang S, Zheng Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. *Front Endocrinol (Lausanne)*. 2021;12:.
8. Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. *Adv Chronic Kidney Dis*. 2018;25(2):121–32.
9. United States Renal Data System. The United States Renal Data System 2024 Annual Data Report [Internet]. 2024 [diakses 28 Mar 2025]. Tersedia pada: [<https://usrds-adr.niddk.nih.gov/2024>]
10. Zhang L, Zhao MH, Zuo L, Wang Y, Yu F, Zhang H, et al. China Kidney Disease Network (CK-NET) 2016 annual data report. *Kidney Int Suppl*. 2020;10(2):e97–185.
11. Perhimpunan Nefrologi Indonesia. 13th Annual Report of Indonesian Renal Registry 2020. 2020.
12. Edwina DA, Manaf A, Efrida. Pola komplikasi kronis penderita diabetes melitus tipe 2 rawat inap di Bagian Penyakit Dalam RS Dr. M. Djamil Padang Januari 2011–Desember 2012. *J Kesehat Andalas*. 2015;4(1):102–6.
13. Zahra ASA, Simanjorang C. Risk factors of chronic kidney disease in Indonesian patients with diabetes mellitus. *Media Kesehat Masy Indones*.

2024;20(3):102–11.

14. Fu H, Liu S, Bastacky SI, Wang X, Tian XJ, Zhou D. Diabetic kidney diseases revisited: a new perspective for a new era. *Mol Metab.* 2019;30:250–63.
15. Rout P, Jialal I. Diabetic nephropathy. *Natl Libr Med.* 2025;.
16. Raja P, Maxwell AP, Brazil DP. The potential of albuminuria as a biomarker of diabetic complications. *Cardiovasc Drugs Ther.* 2021;35(3):455–66.
17. Palmer BF. Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes. *Diabetes Obes Metab.* 2023;25(6):1434–43.
18. Chagnac A, Friedman AN. Measuring albuminuria in individuals with obesity: pitfalls of the urinary albumin-creatinine ratio. *Kidney Med.* 2024;6(4):100804.
19. Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* 2024;105(4):S117–314.
20. Kurniati A, Tahono. Angka banding albumin kreatinin air kemih dan HbA1c serta estimasi laju filtrasi glomerulus pada pasien diabetes melitus tipe 2. *Indones J Clin Pathol Med Lab.* 2015;21(3):250–6.
21. Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. *Diabetes Obes Metab.* 2020;22(S1):3–15.
22. Halim GN. Hubungan mikroalbuminuria (MAU) dan estimasi laju filtrasi glomerulus (eGFR) sebagai prediktor penurunan fungsi ginjal penderita diabetes melitus tipe 2. Universitas Kristen Maranatha; 2017.
23. Parinding VV, Ilmiawan MI, Fitrianingrum L, Trianto HF, Mardhia. Hubungan albuminuria dan laju filtrasi glomerulus pada pasien diabetes melitus tipe 2 yang tidak terkontrol. *J Kesehat Andalas.* 2022;11(2):79–86.
24. Musa AB. Hubungan antara UACR dengan eGFR sebagai penanda gangguan fungsi ginjal pada pasien diabetes melitus tipe 2 RSUPN Dr. Cipto Mangunkusumo. Universitas Indonesia; 2012.
25. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol.* 2009;20(8):1813–21.
26. Fadilatin LA, Aliviameita A. Correlation between urine albumin-creatinine ratio (UACR) value to urine osmolality value and estimate glomerular filtration rate (eGFR) value on patient with kidney failure. *Medica Hosp J Clin Med.* 2024;11(3):295–9.
27. Lerma EV, Batuman V, editors. Diabetes and kidney disease. 2nd ed. Switzerland: Springer; 2022.

28. Wolf G, editor. Diabetes and kidney disease. 1st ed. Wiley-Blackwell; 2013.
29. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. *Nat Rev Dis Primers*. 2015;1(1):15018.
30. Yee J, Krol GD, editors. Chronic kidney disease (CKD): clinical practice recommendation for primary care physicians and healthcare providers—A collaborative approach. 6th ed. Henry Ford Health System; 2011.
31. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels; 2021.
32. Tim Riskesdas 2018. Laporan Nasional Riskesdas 2018. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan (LPB); 2019.
33. Tim Riskesdas 2018. Laporan Provinsi Sumatera Barat Riskesdas 2018. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan (LPB); 2019.
34. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease. *Clin J Am Soc Nephrol*. 2017;12(12):2032–45.
35. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. *Kidney Int Suppl*. 2018;8(1):2–7.
36. ES HS, Decroli E, Afriwardi. Faktor risiko pasien nefropati diabetik yang dirawat di Bagian Penyakit Dalam RSUP Dr. M. Djamil Padang. *J Kesehat Andalas*. 2018;7(2):149–53.
37. Johnson RJ, Floege J, Tonelli M. Comprehensive clinical nephrology. 7th ed. Elsevier; 2024.
38. Natesan V, Kim SJ. Diabetic nephropathy: a review of risk factors, progression, mechanism, and dietary management. *Biomol Ther (Seoul)*. 2021;29(4):365–72.
39. Hoogeveen EK. The epidemiology of diabetic kidney disease. *Kidney Dial*. 2022;2(3):433–42.
40. Marshall CB. Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? *Am J Physiol Cell Physiol*. 2016;311(5):F831–43.
41. Naylor RW, Morais MRPT, Lennon R. Complexities of the glomerular basement membrane. *Nat Rev Nephrol*. 2021;17(2):112–27.
42. Miner JH. The glomerular basement membrane. *Exp Cell Res*. 2012;318(9):973–8.
43. Reiser J, Altintas MM. Podocytes. *F1000Research*. 2016;5:114.
44. Yin L, Yu L, He JC, Chen A. Controversies in podocyte loss: death or detachment? *Front Cell Dev Biol*. 2021;9:.

45. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. *Kidney Int.* 2008;74(1):22–36.
46. Dong R, Xu Y. Glomerular cell cross talk in diabetic kidney diseases. *J Diabetes.* 2022;14(8):514–23.
47. Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation. *J Biol Eng.* 2022;16(1):19.
48. Hu S, Hang X, Wei Y, Wang H, Zhang L, Zhao L. Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review. *Cell Commun Signal.* 2024;22(1):136.
49. Sharma S, Smyth B. From proteinuria to fibrosis: an update on pathophysiology and treatment options. *Kidney Blood Press Res.* 2021;46(4):411–20.
50. Lambers Heerspink HJ, Gansevoort RT. Albuminuria is an appropriate therapeutic target in patients with CKD. *Clin J Am Soc Nephrol.* 2015;10(6):1079–88.
51. Inker LA, Titan S. Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. *Am J Kidney Dis.* 2021;78(5):736–49.
52. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604–12.
53. Verdiansah. Pemeriksaan fungsi ginjal. *Cermin Dunia Kedokt.* 2016;43(2):148–54.
54. Kalfaoglu ME. Evaluation of hepatic/renal and splenic/renal echointensity ratio using ultrasonography in diabetic nephropathy. *Diagnostics.* 2023;13(14):2401.
55. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. *Am J Kidney Dis.* 2013;62(6):1095–101.
56. Seegmiller JC, Bachmann LM. Urine albumin measurements in clinical diagnostics. *Clin Chem.* 2024;70(2):382–91.
57. Nurrahmah N, Kikie Trivia A, Hermin S, Akhmad S. Fast colorimetric detection of albumin-to-creatinine ratio using paper-based analytical devices with alkaline picrate and bromothymol blue reagents. *J Appl Pharm Sci.* 2022;.
58. ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Ekhlaspour L, et al. Chronic kidney disease and risk management: Standards of Care in Diabetes—2024. *Diabetes Care.* 2024;47(Suppl 1):S219–30.
59. National Kidney Foundation. Urine albumin-creatinine ratio (uACR) [Internet]. 2023 [diakses 19 Apr 2025]. Tersedia pada:

[<https://www.kidney.org/kidney-topics/urine-albumin-creatinine-ratio-uacr>]

60. Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, Suzuki K, et al. Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. *Diabetes Care*. 2009;32(8):1518–20.
61. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. 3rd ed. Jakarta: Salemba Medika; 2010.
62. Salsabila AP. Profil pasien nefropati diabetik di Poliklinik Penyakit Dalam RSUP Dr. M. Djamil Padang tahun 2023. Universitas Andalas; 2024.
63. Pratiwi W, Surgana MB. Profile of diabetic nephropathy patients at Waled General Hospital, Cirebon District, Indonesia: high prevalence in productive age group, female and housewives. *J Law Sustain Dev*. 2024;12(6):e3746.
64. Kumar S, Das B. Clinical profile and staging of diabetic nephropathy among patients with type 2 diabetes mellitus. *Int J Curr Pharm Rev Res*. 2024;16(11):368–72.
65. Farah RI, Al-Sabbagh MQ, Momani MS, Albtoosh A, Arabiat M, Abduraheem AM, et al. Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. *BMC Nephrol*. 2021;22(1):223.
66. Tang Y, Jiang J, Zhao Y, Du D. Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity. *Clin Kidney J*. 2024;17(9):.
67. Fabre L, Bevilaqua Rangel É. Age-related markers and predictors of diabetic kidney disease progression in type 2 diabetes patients: a retrospective cohort study. *Ther Adv Endocrinol Metab*. 2024;15:.
68. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: worldwide difference of prevalence and risk factors. *J Nephropharmacol*. 2016;5(1):49–56.
69. Kim CS, Suh SH, Choi HS, Bae EH, Ma SK, Kim B, et al. Impact of diabetes duration and hyperglycemia on the progression of diabetic kidney disease: insights from the KNHANES 2019–2021. *World J Diabetes*. 2025;16(5):.
70. Shi L, Xue Y, Yu X, Wang Y, Hong T, Li X, et al. Prevalence and risk factors of chronic kidney disease in patients with type 2 diabetes in China: cross-sectional study. *JMIR Public Health Surveill*. 2024;10:e54429.
71. Zhang F, Han Y, Zheng G, Li W. Gender differences in the incidence of nephropathy and changes in renal function in patients with type 2 diabetes mellitus: a retrospective cohort study. *Diabetes Metab Syndr Obes*. 2024;17:943–57.
72. Putri NN, Kurniati I, Yuningrum H, Susianti. Hubungan protein urin dengan berat jenis urin pada pasien nefropati diabetik. *J Profesi Kedokt Lampung*. 2025;14(12):2224–8.

73. Pavkov ME, Knowler WC, Bennett PH, Looker HC, Krakoff J, Nelson RG. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. *Kidney Int.* 2006;70(10):1840–6.
74. Piani F, Melena I, Tommerdahl KL, Nokoff N, Nelson RG, Pavkov ME, et al. Sex-related differences in diabetic kidney disease: mechanisms and potential therapeutic implications. *J Diabetes Complications.* 2021;35(4):107841.
75. Gohar EY, Giachini FR, Pollock DM, Tostes RC. Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases. *Life Sci.* 2016;159:20–9.
76. Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Copeptin, insulin resistance, and risk of incident diabetes in older men. *J Clin Endocrinol Metab.* 2015;100(9):3332–9.
77. Muscogiuri G, Barrea L, Annunziata G, Vecchiarini M, Orio F, Di Somma C, et al. Water intake keeps type 2 diabetes away? Focus on copeptin. *Endocrine.* 2018;62(2):292–8.
78. Ubaid S, Osama M, Ullah U, Ud Din Z, Zohaib Ul Hassan M, Hamza M. Evaluating abdominal obesity and BMI as risk factors for diabetic nephropathy in patients with type 2 diabetes mellitus: a case-control study. *Cureus.* 2025;.
79. Kusdiyah E, Makmur MJ, Aras RBP. Karakteristik faktor-faktor risiko terjadinya komplikasi kronik nefropati diabetik dan/atau penyakit pembuluh darah perifer pada penderita diabetes mellitus di RSUD Raden Mattaher tahun 2018. *Electron J Sci Environ Heal Dis.* 2021;1(1):19–32.
80. Viswanathan V, SelvaElavarasan S, Kumpatla S. Increased body mass index is independently associated with chronic kidney disease among people with type 2 diabetes. *Indian J Nephrol.* 2025;35(5):532–8.
81. Lu J, Liu X, Jiang S, Kan S, An Y, Zheng C, et al. Body mass index and risk of diabetic nephropathy: a Mendelian randomization study. *J Clin Endocrinol Metab.* 2022;107(6):1599–608.
82. Ravi H, Das S, Elumalai R, Ramanathan G. Obesity-induced diabetic kidney disease: pathophysiology and clinical manifestations. *J Ren Endocrinol.* 2024;10:e25073.
83. Kovesdy CP, Furth SL, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. *Braz J Med Biol Res.* 2017;50(5):.
84. Ariza D, Ferdhyanti AU, Ikhsan I. Profil anemia pada pasien diabetes mellitus penderita nefropati diabetik. *J Kesehat.* 2022;14(2):116.
85. Elhefnawy KA, Elsayed AM. Prevalence of diabetic kidney disease in patients with type 2 diabetes mellitus. *Egypt J Intern Med.* 2019;31(2):149–54.

86. Liu W, Du J, Ge X, Jiang X, Peng W, Zhao N, et al. The analysis of risk factors for diabetic kidney disease progression: a single-centre and cross-sectional experiment in Shanghai. *BMJ Open*. 2022;12(6):e060238.
87. Davoudi Z, Salmanian Mashhadi M, Mokhtari N, Sheibani M. Blood pressure variability in diabetic patients with or without albuminuria. *J Nephrothol*. 2022;11(1):.
88. Jha R, Lopez-Trevino S, Kankanamalage HR, Jha JC. Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions. *Biomedicines*. 2024;12(5):1098.
89. Sherwood L. *Human physiology: from cells to system*. 9th ed. Cengage Learning; 2016.
90. Chandra N. *Hubungan tekanan darah terhadap kejadian nefropati diabetik pada pasien DM tipe 2 di RS Bethesda Yogyakarta*. Universitas Kristen Duta Wacana; 2015.
91. Yamao Y, Ota M, Kanasaki K. Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use. *Diabetol Int*. 2025;.
92. Iwata Y, Okushima H, Hesaka A, Kawamura M, Imamura R, Takahara S, et al. Identification of diabetic nephropathy in patients undergoing kidney biopsy through blood and urinary profiles of D-serine. *Kidney360*. 2021;2(11):1734–42.
93. Orchi P, Zaman MB, Faruque FB, Susmita SJ, Begh TJ. Progression of diabetic nephropathy in patients with uncontrolled type 2 diabetes mellitus: a cross-sectional study. *Int J Adv Med*. 2025;12(4):362–5.
94. Saputro AA, Rusidah Y. Analisis kadar mikroalbuminuria pasien lansia dengan riwayat diabetes mellitus tipe II di Kabupaten Kudus. *Kolok Penelit Univ Pros*. 2023:157–65.
95. Bhowmick K, Kuttu AVM, Shetty HV. Glycemic control modifies the association between microalbuminuria and C-reactive protein in type 2 diabetes mellitus. *Indian J Clin Biochem*. 2007;22(2):53–9.
96. Wahyuni F. *Korelasi kadar hemoglobin terglikasi dengan urinary albumin-creatinine ratio pada diabetes melitus tipe 2*. Universitas Andalas; 2016.
97. Tang WH, Hung WC, Wang CP, Wu CC, Hsuan CF, Yu TH, et al. The lower limit of reference of urinary albumin/creatinine ratio and the risk of chronic kidney disease progression in patients with type 2 diabetes mellitus. *Front Endocrinol (Lausanne)*. 2022;13:.
98. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. *PLoS Med*. 2008;5(10):e207.

99. Kataoka H, Nitta K, Hoshino J. Glomerular hyperfiltration and hypertrophy: an evaluation of maximum values in pathological indicators to discriminate “diseased” from “normal.” *Front Med.* 2023;10:.
100. Schnaper HW. Remnant nephron physiology and the progression of chronic kidney disease. *Pediatr Nephrol.* 2014;29(2):193–202.
101. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int.* 2021;99(3):S1–87.
102. Ma’shumah N, Bintanah S, Handarsari E. Hubungan asupan protein dengan kadar ureum, kreatinin, dan kadar hemoglobin darah pada penderita gagal ginjal kronik hemodialisa rawat jalan di RS Tugurejo Semarang. *J Gizi Univ Muhammadiyah Semarang.* 2014;3(1):22–32.
103. Fortuna F, Yuniarti E. Pengaruh latihan beban terhadap kadar kreatinin pada anggota Pusat Kebugaran Universitas Negeri Padang. *Pros Semin Nas Biol.* 2022;1(2):1686–92.
104. Yamanouchi M, Sawa N, Toyama T, Shimizu M, Oshima M, Yoshimura Y, et al. Trajectory of GFR decline and fluctuation in albuminuria leading to end-stage kidney disease in patients with biopsy-confirmed diabetic kidney disease. *Kidney Int Rep.* 2024;9(2):323–33.

